
|Articles|April 1, 1998
Issues and Controversies in Pharmacoeconomics
Advertisement
Articles in this issue
over 27 years ago
Participating Facultyover 27 years ago
Coronary Heart Disease in the United Statesover 27 years ago
Mechanisms of Acute Coronary Eventsover 27 years ago
Primary Preventionover 27 years ago
Pravastatin Event Reduction Analysisover 27 years ago
Secondary Preventionover 27 years ago
Point/Counterpoint: Is LDL-C Reduction the Outcome of Choice?over 27 years ago
Methods and Mindsets in Pharmacoeconomicsover 27 years ago
Pharmacoeconomics Perspectives: Payers, Providers, and PatientsNewsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant for ER+ and HER2-Negative Breast Cancer
2
In Primary Care–Oncology Collaboration, the Baton Goes Both Ways
3
Marathon Health, Medbridge Partner to Launch Integrated Virtual MSK Care Program
4
Myasthenia Gravis–Induced Fears of Diagnosed Patients During the Pandemic
5